-
4m 53sPart 2 | Session 6 NUDGE-FLU: Increasing Influenza Vaccination in HF Patients
-
3m 56sPart 2 | Session 7 DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF
-
5m 11sPart 2 | Session 8 TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure
-
8m 22sPart 2 | Session 9 Diagnosis in Heart Failure in Women
-
3m 50sPart 2 | Session 10 Dapagliflozin and Peripheral Arterial Disease in Heart Failure
-
26m 30sPart 1 | Session 1 Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney
-
5m 48sPart 1 | Session 2 The PARAGLIDE-HF Trial
-
13m 32sPart 1 | Session 3 HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi
-
4m 3s
-
2m 45sPart 2 | Session 1 MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring
-
6m 54s
-
3m 11sPart 2 | Session 3 APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis
-
4m 45sPart 2 | Session 4 DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction
Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from HFA 2023 revealed that dapagliflozin administration in stable out-setting chronic HF patients with optimised therapy resulted in global reverse remodelling of cardiac structure, including reduced LA volumes, improved LV geometry and decreased NT-proBNP concentrations at 180 days.
Interview Questions:
1. What is known about SGLT2is' mechanism and study importance?
2. What is the study design, methodology, and outcomes?
3. What are the key findings?
4. What are the take-home messages?
5. How do the effects of dapagliflozin compare with other available treatments?
Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.
Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.
For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.
Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023.
Comments